MHRA Approves Catumaxomab for Cancer Ascites | World Arthritis Day | Leeds Medicine Spotlight

The MHRA approved catumaxomab (Korjuny) on 7 October to treat malignant ascites—a build-up of fluid containing cancer cells in the abdomen—in adults when standard cancer treatment is no longer feasible.

Malignant ascites places a considerable burden on patients, who often require repeated procedures to drain the fluid. Catumaxomab is a monoclonal antibody that targets a protein called epithelial cell adhesion molecule (EpCAM) found on certain cancer cells. It activates the immune system to destroy these cells, extending the time between drainage procedures.

In the pivotal trial of 258 patients with EpCAM-positive cancer and malignant ascites who had no further chemotherapy options, patients receiving catumaxomab after drainage did not require further procedures for around 46 days, compared with just 11 days for those treated with drainage alone.

This approval offers patients living with advanced cancer an additional option that can meaningfully improve quality of life when curative treatment is no longer possible. The drug is administered under medical supervision, and as with all licensed medicines, the MHRA will continue to monitor its safety closely.

Why it matters for interviews

Malignant ascites exemplifies how treatment shifts from cure to symptom control in palliative care. Interviewers may explore your understanding of quality of life versus life extension, the role of innovative immunotherapies in end-of-life care, and how clinicians balance non-maleficence (avoiding repeated invasive drainage) with beneficence (extending symptom-free intervals). Understanding palliative intent in advanced disease demonstrates maturity in your clinical thinking.

For a deeper dive into balancing ethical principles in treatment decisions, explore The Four Pillars of Medical Ethics.

Tomorrow marks World Arthritis Day, observed annually on 12 October to raise awareness of arthritis—a term covering over 100 conditions affecting the joints, including rheumatoid arthritis (RA) and osteoarthritis.

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system mistakenly attacks the synovial lining of joints, causing inflammation, pain, and progressive damage. In 2020, an estimated 17.6 million people worldwide lived with RA, with women affected two to three times more often than men. Peak onset occurs between ages 50 and 59, though RA can develop at any age.

Symptoms include swollen, tender joints—particularly in the hands and feet—and morning stiffness lasting longer than 30 minutes. The inflammation can lead to permanent joint damage and disability if untreated. RA is also systemic, affecting the heart, lungs, eyes, and other organs. Risk factors include smoking, obesity, family history, and exposure to air pollution.

Early diagnosis and prompt treatment with disease-modifying therapies can prevent progression in up to 90% of patients. In high-income countries, around 75–80% of patients achieve remission or low disease activity, though access remains inequitable globally.

Critical analysis

World Arthritis Day highlights an important tension: awareness versus equity. While high-income countries offer biological therapies and early intervention, remission rates in low- and middle-income settings are far lower due to inadequate access. Awareness campaigns can inadvertently deepen health inequalities if they do not address systemic barriers—cost, geography, specialist availability—that prevent equitable care.

For applicants, this day offers an opportunity to reflect on social determinants of health and the global disparities in managing chronic disease. It also underscores the importance of early recognition in primary care and the role of multidisciplinary teams—rheumatologists, physiotherapists, occupational therapists, and mental health support—in optimising long-term outcomes.

Awareness days are most powerful when they translate into action: improved GP training, faster referral pathways, and investment in research that benefits all populations, not just those who can afford it.

The approval of catumaxomab for malignant ascites raises a question central to modern palliative care: when does intervention become burden rather than benefit?

Malignant ascites occurs when cancer spreads to the peritoneum, causing fluid to accumulate in the abdomen. Drainage (paracentesis) offers temporary relief but requires repeated hospital procedures—an invasive cycle that can dominate a patient's final months. Catumaxomab extends the interval between drainages, but it does not cure the underlying cancer and carries its own side effects.

The ethical tension

This scenario sits at the intersection of beneficence (offering treatment that prolongs symptom-free time), non-maleficence (minimising harm from repeated invasive procedures), autonomy (respecting patient choice about trade-offs), and justice (allocating resources in end-of-life care).

Some patients may prioritise time at home over frequency of treatment; others may value every symptom-free day, regardless of how it is achieved. The clinician's role is not to impose a "correct" answer but to facilitate an informed decision grounded in the patient's values, prognosis, and quality-of-life goals.

Discussion points for interviews

- How do you balance autonomy with beneficence when a patient requests a treatment that prolongs life minimally but carries significant burden?
Autonomy does not mean patients decide in isolation. Clinicians must provide realistic prognostic information, explore what matters most to the patient, and support shared decision-making.

- What role does non-maleficence play in end-of-life care?
"Do no harm" evolves in palliative settings: harm may include futile interventions, prolonged suffering, or denying a peaceful death. Stopping active treatment is not abandonment—it is a shift to comfort-focused care.

- How should resource allocation influence decisions in terminal illness?
Justice requires us to consider opportunity cost. High-cost palliative therapies must be weighed against preventive or curative interventions elsewhere. Transparent, compassionate conversations about prognosis help patients make decisions aligned with their priorities, not unrealistic hope.

Palliative care is not about giving up; it is about refocusing what medicine can—and should—achieve. This distinction is central to practicing with integrity in an NHS constrained by finite resources and infinite need.

For structured frameworks to discuss these dilemmas, visit The Four Pillars of Medical Ethics.

You will be asked about diseases, treatments, and scenarios you have never encountered clinically. That is not a test of your medical knowledge—it is a test of how you think, communicate, and apply principles under pressure.

Consider this question: "What do you know about rheumatoid arthritis?"

A weak answer lists symptoms from memory. A strong answer demonstrates structure, insight, and curiosity.

Build a framework, not a fact dump

When discussing any condition, use a consistent structure:

• What it is: A brief, accurate definition (e.g. "Rheumatoid arthritis is a chronic autoimmune condition where the immune system attacks the synovial lining of joints").
• Who it affects: Epidemiology and risk factors (e.g. "It predominantly affects women, often presents between ages 50–59, and risk factors include smoking and family history").
• How it presents: Key symptoms and signs (e.g. "Patients experience symmetrical joint pain and swelling, particularly in the hands and feet, with morning stiffness lasting over 30 minutes").
• Why it matters: Impact on quality of life and the role of early intervention (e.g. "Untreated RA can cause permanent joint damage and disability, but early disease-modifying therapy can achieve remission in most patients").

This structure works for any condition and demonstrates you can organise information logically—a skill essential to clinical practice.

Show, don't tell, your intellectual curiosity

If you have read about RA, explain why. For example:
"I became interested in autoimmune conditions after reading about the role of biologics in transforming RA outcomes. It made me reflect on how early diagnosis in primary care can make such a difference to long-term prognosis."

This signals genuine engagement, not box-ticking.

What to do when you don't know

If asked about a condition you truly know nothing about, say so honestly, then show how you would approach learning:

"I'm not familiar with that condition, but I'd want to understand what causes it, how it presents, and what treatment options exist. Could you tell me more, or would you like me to reason through what it might involve based on the name?"

This demonstrates humility, adaptability, and a problem-solving mindset—all more valuable than memorised facts.

Practice with intent

Choose five conditions across different systems (cardiovascular, respiratory, rheumatological, neurological, psychiatric). For each, build a two-minute answer using the framework above. Then practise delivering it aloud, as if in conversation.

Medicine rewards those who can think clearly under uncertainty. Interviews reward those who can communicate that clarity to others.

For structured practice on current topics and ethical scenarios, visit Interview Preparation.

Interview preparation is not about cramming facts the week before. It is about building habits that compound into fluency, confidence, and clarity. Here are three five-minute practices that deliver outsized returns.

1. Read one medical story aloud every morning

Choose a short news article—from the NHS, NICE, BMJ, or this newsletter—and read it aloud. Then immediately summarise it in two sentences, as if explaining it to a friend.

Why it works: Speaking aloud builds verbal fluency. Summarising forces you to identify what matters. Both are interview skills, practiced daily in a low-pressure environment. By the time you sit down in an interview, articulating medical concepts will feel automatic.

2. Keep a "one-line-per-day" reflection journal

At the end of each day, write one sentence reflecting on something you learned, observed, or questioned. It could be from a lecture, a conversation, work experience, or something you read.

Example:
"Today I learned that rheumatoid arthritis can affect the lungs and heart, not just joints—reminded me that 'systemic' really means systemic."

Why it works: Interviewers ask about reflection constantly. This habit builds a bank of genuine, specific examples you can draw on. One line is frictionless—no pressure, no perfectionism—but it trains your brain to notice and articulate growth.

3. Explain one concept to someone who knows nothing about medicine

Once a week, pick a term or concept—autonomy, herd immunity, monoclonal antibodies—and explain it to a parent, sibling, or friend in under 60 seconds, without jargon.

Why it works: Medicine is full of complexity, but good doctors make complexity accessible. If you can explain EpCAM-targeting antibodies to someone who has never heard of them, you can certainly explain your thinking to an interviewer. This is also exactly what you will do with patients.

The compound effect

None of these habits take more than five minutes. But done consistently, they build fluency, reflection, and communication—the three qualities interviewers assess most.

Interview preparation is not a sprint in October. It is a series of small, deliberate actions taken every day. Start today.

For structured guidance on building your interview skillset, explore Interview Preparation and Structuring Answers Under Pressure.

The University of Leeds offers a well-established five-year MBChB programme (A100), alongside a Gateway Year route (A101) for widening participation applicants. Leeds is a UCAT school with a strong emphasis on academic achievement, contextual admissions, and integrated clinical exposure from Year 1.

Entry requirements

A-levels: AAA including Chemistry and Biology. A fourth A-level does not provide an advantage, and A grades do not compensate for lower performance (i.e. AA*B is not accepted in place of AAA). Certain combinations—such as Chemistry with Biology and Human Biology, or Chemistry with Biology and Sports Science—are not accepted.

GCSEs: Minimum of six at grade 6 or above, including Maths, English Language, Biology, and Chemistry (or Dual Science). All Level 2 qualifications must be achieved by the time of application. Leeds scores applicants on eight GCSEs, so those applying with only the minimum are unlikely to be shortlisted.

Resits: From 2026 entry onwards, Leeds accepts one resit attempt per Level 3 and Level 2 qualification without mitigating circumstances. Third attempts are only considered with appropriate evidence of disruption.

Graduates: Minimum 2:1 honours degree in any discipline (awarded within the last three years), plus A-levels at ABB including Chemistry and Biology (one at grade A). Graduate applicants with below a 2:1 are only considered if they can demonstrate substantial subsequent healthcare or professionally demanding experience.

Access to HE Diplomas: Accepted if they conform to the QAA subject descriptor, with all 60 credits passed and all graded Level 3 units at distinction. Distance-learning Access courses are not accepted. Access applicants who completed A-levels or a degree fewer than three years prior are also not eligible.

International qualifications: IB requires 36 points overall, with 6 in three Higher Level subjects including Chemistry and Biology. If English and Maths are not offered at GCSE, a minimum of 5 at Standard Level is required.

Contextual admissions (Access to Leeds)

Leeds operates a comprehensive widening participation scheme. Applicants are eligible if they meet two or more of the following criteria:

• Household income of £25,000 or below, or in receipt of 16–19 Bursary Fund or free school meals during GCSE studies
• First generation in immediate family to attend university
• Attended a school achieving below the national average at GCSE (Attainment 8 score)
• Studies disrupted by personal, social, or domestic circumstances
• Live in a postcode area with low progression to higher education (check via Leeds' online tool)
• Lived or grew up in public care

Contextual applicants receive adjusted offers and additional consideration during shortlisting.

UCAT

Leeds uses the UCAT as part of its scoring system for interview selection. While the school does not publish a specific cut-off, applicants should aim for a competitive score—typically in the upper quartiles—particularly if applying without contextual flags. For data-driven insights into UCAT thresholds, explore TrueScore – UCAT Predictions.

Curriculum and clinical exposure

Leeds follows an integrated, spiral curriculum combining basic sciences, clinical skills, and patient contact from Year 1. Early clinical placements take place across Yorkshire hospitals and GP practices, with increasing responsibility in later years. The programme prepares students for the GMC Medical Licensing Assessment (MLA), and successful completion allows provisional registration with the GMC.

Leeds has a strong reputation for research, particularly in musculoskeletal medicine, cardiovascular disease, and cancer. Students can intercalate a BMedSci after Year 3 or Year 4, subject to academic performance.

Gateway Year to Medicine (A101)

The Gateway Year is a six-year route for widening participation applicants who meet the contextual criteria but have lower predicted grades (typically BBC including Chemistry or Biology at grade B, plus Physics or Maths if Chemistry is not taken). The foundation year provides intensive academic preparation before progressing to the standard five-year MBChB.

Applicants predicted ABB with an A in Chemistry or Biology and meeting widening participation criteria should apply via the Access to Leeds route to A100, not A101. Graduate applicants and those who have completed previous Access or foundation courses are not eligible for A101.

What Leeds values

Leeds prioritises academic excellence, contextual awareness, and a clear commitment to medicine. The school does not require formal clinical work experience but expects applicants to demonstrate insight into the realities of a medical career through whatever experiences are accessible to them. Reflection, not just participation, is key.

Leeds is transparent about its selection criteria and publishes detailed guidance on resits, contextual flags, and GCSE scoring. Applicants should read the course entry requirements carefully and use the Access to Leeds postcode checker if applicable.

Key links

• University of Leeds Medicine (A100) – UCAS
• University of Leeds Medicine (A100) – Medical Schools Council
• Application Strategy – NextGenMedPrep
• TrueScore – UCAT Predictions
• Medical School Rankings

Bottom line

Leeds is an academically demanding school with a genuine commitment to widening participation. If you meet the contextual criteria, it offers one of the most supportive routes into medicine in the UK. If you don't, ensure your grades—both GCSE and A-level—are competitive, and that your UCAT score is strong. Leeds rewards preparation, precision, and a clear understanding of what the school is looking for.